Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Blocklisting Six Monthly Return

29 Jun 2015 07:00

RNS Number : 4650R
Hutchison China Meditech Limited
29 June 2015
 

 

 

 

Blocklisting Six Monthly Return

 

 

London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 

Hutchison China MediTech Limited

2.

Name of scheme:

 

Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:

 

From 29 December 2014 to 28 June 2015

4.

Balance under scheme from previous return:

 

696,051 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 

Nil

6.

Number of securities issued/allotted under scheme during period:

223,288 ordinary shares of US$1 each

7.

Balance under scheme not yet issued/allotted at end of the period:

 

472,763 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:

53,299,964 ordinary shares of US$1 each

Name of contact:

 

Christian Hogg

Address of contact:

 

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 

+852 2121 8200

 

 

Ends

 

 

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

 

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

 

About Chi-Med

 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit: www.chi-med.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRUKSVRVWANURR
Date   Source Headline
5th Jul 20117:00 amRNSNotice of Results
29th Jun 20117:00 amRNSBlocklisting Interim Review
13th May 20118:25 amRNSHolding(s) in Company
9th May 20111:18 pmRNSResult of AGM
9th May 20117:00 amRNSHolding(s) in Company
4th Apr 20117:00 amRNS2010 Annual Report and Notice of AGM
28th Mar 201112:28 pmRNSDirector/PDMR Shareholding
9th Mar 20117:00 amRNSFinal Results
21st Feb 20117:00 amRNSBoard Change
15th Feb 20117:00 amRNSAppointment of UBS Limited as Joint Broker
1st Feb 20117:00 amRNSFruquintinib starts Phase I cancer clinical trial
31st Jan 20119:00 amRNSNotice of Results
5th Jan 20119:00 amRNSTotal Voting Rights
29th Dec 20109:00 amRNSBlocklisting Interim Review
21st Dec 20107:00 amRNSSBCVC Investment in MediPharma
10th Dec 20107:00 amRNSIncreases indirect ownership of OTC joint venture
8th Nov 20107:00 amRNSHutchison MediPharma Receives Strategic Investment
20th Sep 20107:00 amRNSOrganic Infant formula launched in China
15th Sep 20107:00 amRNSAppointment of Joint Broker
29th Jul 20107:00 amRNSInterim Results
14th Jul 20109:18 amRNSHolding(s) in Company
7th Jul 20109:26 amRNSHolding(s) in Company
7th Jul 20107:00 amRNSNotice of Results
5th Jul 20108:58 amRNSTotal Voting Rights
29th Jun 20101:59 pmRNSBlocklisting Six Monthly Return
25th Jun 20109:50 amRNSDirector/PDMR Shareholding
17th Jun 20109:01 amRNSHolding(s) in Company
30th Apr 20101:18 pmRNSResult of AGM
30th Apr 20107:00 amRNSPhase I Trial of Sulfatinib for Cancer Initiated
19th Apr 20107:00 amRNSIP protection for main prescription drug extended
29th Mar 20107:00 amRNS2009 Annual Report and Notice of AGM
15th Mar 20109:15 amRNSHolding(s) in Company
12th Mar 20109:40 amRNSHolding(s) in Company
10th Mar 201010:47 amRNSHolding(s) in Company
8th Mar 20109:13 amRNSHolding(s) in Company
4th Mar 20107:00 amRNSFinal Results
8th Feb 20109:00 amRNSNotice of Results
2nd Feb 201011:24 amRNSTotal Voting Rights
19th Jan 20107:00 amRNSMore drugs added to Chinese Medicines Catalogue
4th Jan 20109:20 amRNSTotal Voting Rights
29th Dec 20099:05 amRNSBlocklisting Interim Review
26th Nov 20097:00 amRNSHolding(s) in Company
5th Nov 200910:23 amRNSSuccessful Phase IIb UC Trial for HMPL-004
30th Oct 20097:00 amRNSInitiates Phase I Clinical Trial of HMPL-011
26th Oct 20097:00 amRNSAcquires 100% of Hutchison Healthcare JV
16th Oct 20097:00 amRNSStatement on Essential Medicines List
8th Oct 20097:00 amRNSJoint venture with The Hain Celestial Group
27th Aug 20097:00 amRNSKey Drugs in New National Essential Medicines List
30th Jul 20097:00 amRNSInterim Results
29th Jul 20097:00 amRNSEnrolment of HMPL-004 Phase IIb UC Trial Completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.